Article Text

Download PDFPDF
Conservative Treatment With Medroxyprogesterone Acetate Plus Levonorgestrel Intrauterine System for Early-Stage Endometrial Cancer in Young Women: Pilot Study
  1. Mi Kyung Kim, MD*,
  2. Bo Sung Yoon, MD*,
  3. Hyun Park, MD*,
  4. Seok Ju Seong, MD, PhD*,
  5. Hyun Hoon Chung, MD,
  6. Jae Weon Kim, MD and
  7. Soon Beom Kang, MD
  1. * Department of Obstetrics and Gynecology, Gangnam CHA Medical Center, CHA University; and
  2. Department of Obstetrics and Gynecology, Seoul National University, College of Medicine, Seoul, Korea.
  1. Address correspondence and reprint requests to Seok Ju Seong, MD, PhD, Department of Obstetrics and Gynecology, Gangnam CHA Medical Center, CHA University, 650-9, Yoksam-dong, Gangnam-gu, Seoul, Korea, 135-913. E-mail: sjseongcheil{at}yahoo.co.kr.

Abstract

Objective: To assess the feasibility of using medroxyprogesterone acetate (MPA) and levonorgestrel intrauterine system (LNG-IUS) to treat early-stage endometrial cancer in young women who want to preserve their reproductive potential.

Methods: Prospective observational study of 5 young patients (mean [SD] age, 38.4 [4.8] years; range, 33-41 years) with a grade 1 endometrial cancer that is presumably confined to the endometrium. The subjects were given a daily oral dose of 500 mg of MPA and LNG-IUS placement. They were followed with dilation and curettage every 3 months.

Results: Complete remission was shown in 4 of 5 patients, and one patient showed partial remission. Biopsy results were negative in 2 patients at 3 months, in 1 patient at 6 months, and in 1 patient at 12 months. No treatment-related complications occurred. No recurrence was found during the follow-up period (mean [SD], 10.2 [3.6] months; range, 6-16 months).

Conclusions: The concomitant use of MPA with LNG-IUS is feasible for conservative treatment of early-stage endometrial cancer in young women who want to preserve their reproductive potential.

  • Endometrial cancer
  • Progesterone
  • LNG-IUS
  • Medroxyprogesterone acetate
  • Levonorgestrel

Statistics from Altmetric.com

Footnotes

  • The authors have no conflict of interest to declare.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.